Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide

PACTRIMS 2017

(2018)   Multiple Sclerosis Journal

PACTRIMS 2017

(2018)   Multiple Sclerosis Journal

Poster Session 2

(2018)   Multiple Sclerosis Journal

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Long-term safety and efficacy of teriflunomide

(2016) Paul O'Connor et al.   NEUROLOGY

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

(2016) Ludwig Kappos et al.   Multiple Sclerosis Journal

Optimizing treatment success in multiple sclerosis

(2015) Tjalf Ziemssen et al.   JOURNAL OF NEUROLOGY

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study

(2015) D. H. Miller et al.   NEUROLOGY

Fingolimod effect on brain volume loss independently contributes to its effect on disability

(2015) MP Sormani et al.   Multiple Sclerosis Journal

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

(2014) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

Brain atrophy and lesion load predict long term disability in multiple sclerosis

(2013) Veronica Popescu et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

(2013) Jerry S Wolinsky et al.   Multiple Sclerosis Journal

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating and reducing the impact of white matter lesions on brain volume measurements

(2011) Marco Battaglini et al.   HUMAN BRAIN MAPPING

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

(2010) N. De Stefano et al.   NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cortical Lesions and Atrophy Associated With Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis

(2009) Massimiliano Calabrese et al.   ARCHIVES OF NEUROLOGY

Gray matter atrophy in multiple sclerosis: A longitudinal study

(2008) Elizabeth Fisher et al.   ANNALS OF NEUROLOGY

Brain Atrophy Assessment in Multiple Sclerosis: Importance and Limitations

(2008) Antonio Giorgio et al.   NEUROIMAGING CLINICS OF NORTH AMERICA